About PILA PHARMA

Pila Pharma AB is a clinical stage pharmaceutical company based in Malmö, Sweden and listed on Nasdaq First North GM, Stockholm, since July 2021.

The company is whole owner of private Danish subsidiary Pila Pharma Danmark ApS and is developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of type 2 diabetes and the rare disease erythromelalgia.

XEN-D0501 has shown good safety in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion.

In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia.
The company is currently completing 13 week preclinical safety studies in 2 animal species with the aim of progressing XEN-D0501 into 3 months phase 2b clinical trials in type 2 diabetes. In addition, a clinical development plan for the orphan indication has been developed and a proof-of-concept trial is being planned in erythromelalgia.

The company welcomes partners and investors for the next development stages.